Multiplex Cytokine Assay and Cytokine Release Assay by PhDs at 20+ Year, FDA-Inspected Lab

Cytokines are important proteins that help control immune responses, inflammation, and how cells communicate with each other. They are small signaling molecules made by different types of cells, especially immune cells, and they can affect how cells grow, develop, and survive. Tests for cytokines measure their levels, giving useful information about how the immune system works and how diseases progress.

Cytokine release syndrome (CRS) happens when a large amount of cytokines is released into the blood, causing inflammation and possible harm to organs and tissues. It is often linked to certain cancer treatments like CAR T-cell therapy and severe infections. Checking cytokine levels with tests like cytokine panels and multiplex cytokine testing can help identify and manage CRS by pinpointing the specific cytokines involved in the inflammation.

A cytokine storm is runaway cytokine release that turns the immune response into the injury; cytokine release syndrome is its clinical form, and it is a first-order safety question for T-cell engagers, CAR-T and agonist antibody programs. That is why sponsors assess CRS risk in vitro before first-in-human: PBMC and whole blood stimulation assays read on multiplex panels, designed around your molecule’s mechanism, framed for the safety package.

A cytokine panel is a lab test that measures the levels of several cytokines at the same time, providing information about immune function, inflammation, and disease processes. It is often used in clinical settings to diagnose or track conditions like autoimmune diseases, infections, and inflammatory disorders. Panels may include cytokines such as Interleukin (IL), Interferons, and TNF-alpha, and can be tailored to the specific condition being examined. Our cytokine panel services use advanced techniques like cytokine ELISA and multiplex testing for precise and thorough results.

A multiplex cytokine assay is a lab method that measures several cytokines at once from one sample. This efficient technique is great for examining complex immune responses and inflammation. It gives a wide view of the cytokines linked to diseases like cancer, autoimmune issues, and infections. Our multiplex cytokine assays offer clear insights into how cytokines interact and their impact on disease development.

Pro-inflammatory cytokines are substances that encourage inflammation, usually due to infection, injury, or immune system activity. Examples include TNF-alpha, IL-6, and IL-1, which are key in triggering inflammation. Testing the levels of these cytokines can give valuable insights into chronic inflammation, autoimmune diseases, and other inflammatory issues.

Our cytokine analysis services can be performed on various biological samples, including plasma, serum, urine, cerebrospinal fluid (CSF), PBMC isolates, tissue lysates, and cell culture supernatants. Each sample type is analyzed with high sensitivity using cutting-edge platforms to ensure reliable results.

We utilize advanced bioanalytical platforms for multiplex cytokine testing, including Meso Scale Discovery, Luminex, AlphaLISA, ELISA, qPCR/ddPCR, and LC-MS/MS. These platforms ensure ultra-sensitive detection and accurate quantification of cytokines across various sample types.

Yes, we offer customized multiplex cytokine assays tailored to specific therapeutic studies. Whether you are investigating cytokine release syndrome (CRS), inflammation responses, or pharmacodynamics, our assays are developed to meet the specific needs of your study, using a range of platforms and assay formats.

GLP validation proves the panel performs before study samples run: accuracy, precision, dilution linearity, stability and analyte-by-analyte acceptance criteria, executed on qualified equipment under Part 58 discipline, typically inside four to six weeks. Fit-for-purpose qualification serves exploratory endpoints; GLP validation is what lets a cytokine number stand in a regulated submission.

That is the standard failure of multiplex work and the reason an escalation path exists. The analytes that matter move to a more sensitive platform, ultrasensitive singleplex or a custom build, until femtogram-per-mL territory is reachable, while the well-behaved analytes stay multiplexed. You keep breadth where breadth works and buy sensitivity only where the biology demands it.

Yes. In vitro CRS risk is assessed in PBMC and whole blood stimulation formats, read on a multiplex panel, with the assay design matched to your molecule’s mechanism, T-cell engager, CAR-T, agonist antibody, and the readout framed for the safety package your regulator will read.

The analyte list decides. If validated kit panels cover your analytes and species, we map your list across vendors and qualify the best fit, which is faster and cheaper. Where an analyte has no kit, no species variant, or no sensitivity headroom, we build custom, with in-house conjugation, and qualify it to the same tier as the rest of the panel so the dataset reads as one assay, not a patchwork.